ONCY presentation today 12 Oct!

ONCY will be presenting a company overview at the 17th Annual Biopartnering Europe Conference in London, U.K. today at 10:15am

This is one biotech stock you would want to keep your eye on for a number of reasons: firstly, In this fourth quarter, the company is expected to present results of a Phase 2 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers having reached a Special Protocol Agreement with the FDA on the design of a Phase 3 trial for REOLYSIN in head and neck cancers, according to an October 2nd Press Release. In this release the company stated that it expects updated results of its phase 2 trial to be presented in the fourth quarter and the company will be presenting for the first time this quarter since that press release: COULD THE COMPANY BE RELEASING UPDATED RESULTS AT THIS CONFERENCE?!!!

Should Oncolytics Biotech Inc. present phase 2 results today, the following information should help you: The company's decision to pursue a Phase 3 trial in head and neck cancers was predicated on positive results seen in the Company’s U.K. Phase 1 and Phase 2 combination REOLYSIN and paclitaxel/carboplatin clinical trials, as well as significant preclinical work demonstrating synergy in combination with taxane or platinum-based drugs. Interim results of the U.K. Phase 1/2 trial reported in March 2009 demonstrated an overall response rate (PR and CR) of 42% and a total clinical benefit rate (PR + CR + stable disease) of 75% and Did I mention that the company reached a Special Protocol agreement with the FDA?
http://www.newswire.ca/en/releases/archive/October2009/07/c4785.html